ZOOZ vs SMLR vs JPM

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -76. 3% for ZOOZ Strategy Ltd. (ZOOZ). Semler Scientific, Inc. (SMLR) offers the better valuation at 4. 0x trailing P/E, making it the more compelling value choice. Analysts rate Semler Scientific, Inc. (SMLR) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Semler Scientific, Inc.

(SMLR) is the cheapest at 4. 0x versus JPMorgan Chase & Co. at 16. 6x.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 0%, compared to -93. 2% for ZOOZ Strategy Ltd. (ZOOZ). Over 10 years, the gap is even starker: SMLR returned +1125% versus ZOOZ's -93. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Semler Scientific, Inc. 's 3. 02β — meaning SMLR is approximately 220% more volatile than JPM relative to the S&P 500. On balance sheet safety, Semler Scientific, Inc. (SMLR) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus -76. 3% for ZOOZ Strategy Ltd. (ZOOZ). On earnings-per-share growth, the picture is similar: Semler Scientific, Inc. grew EPS 95. 1% year-over-year, compared to -886. 2% for ZOOZ Strategy Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Semler Scientific, Inc.

(SMLR) is the more profitable company, earning 72. 7% net margin versus -225. 1% for ZOOZ Strategy Ltd. — meaning it keeps 72. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMLR leads at 37. 2% versus -215. 1% for ZOOZ. At the gross margin level — before operating expenses — SMLR leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SMLR: 148.

4% to $50. 50.

In this comparison, JPM (1.

8% yield) pays a dividend. ZOOZ, SMLR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 8% yield, +495. 3% 10Y return). ZOOZ Strategy Ltd. (ZOOZ) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +495. 3%, ZOOZ: -93. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZOOZ (Industrials) and SMLR (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZOOZ is a small-cap quality compounder stock; SMLR is a small-cap deep-value stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ZOOZ, SMLR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.